Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Michio Yagi"'
Publikováno v:
The Journal of Dermatology. 48:1640-1651
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus, xerosis, and eczematous lesions. In Japan, treatment options, such as topical corticosteroids and tacrolimus, are associated with efficacy and safety concerns. C
Autor:
Kayo Fujita, Mizuki Yoshida, William C. Ports, Akinobu Shoji, Ryosuke Ono, Michio Yagi, Vivek S. Purohit
Publikováno v:
The Journal of dermatologyReferences. 47(1)
Crisaborole ointment, 2%, is a non-steroidal phosphodiesterase 4 inhibitor for the treatment of mild to moderate atopic dermatitis (AD). This parallel-cohort, phase 1 study was conducted to investigate skin irritation potential and safety of crisabor
Autor:
Masahiro Igarashi, Michio Yagi, Fumiaki Ueno, Tsutomu Sakurai, Hidetoshi Furuie, Yutaka Endo, Mitsunori Seki, Saiko Yamada, Nagamu Inoue, Hiroshi Hirato
Publikováno v:
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 44:53-60
Autor:
Michio Yagi, Yoshio Yamaoka, Hiroyasu Yamashiro, Takashi Inamoto, Yasuo Matsutani, Hironori Kato, Masaya Ueno, Akira Yamauchi, Junji Yodoi, Hajime Nakamura, Rei Takahashi, Hiroshi Masutani
Publikováno v:
Immunology letters. 75(1)
Expression of thioredoxin (TRX), a dithiol-reducing enzyme, and mutations of p53 have been detected in various cancer tissues. We recently reported that TRX-dependent redox regulation plays a crucial role in DNA binding activity of p53. In this study
Autor:
Yuta Tsuji, Yasuhiro Kitamura, Masao Someya, Toshihiko Takano, Michio Yaginuma, Kohei Nakanishi, Kazunari Yoshizawa
Publikováno v:
ACS Omega, Vol 4, Iss 3, Pp 4491-4504 (2019)
Externí odkaz:
https://doaj.org/article/f543b9b5d5714671ad96a01870920ad2
Autor:
Hiroyasu Yamashiro, Takashi Inamoto, Michio Yagi, Masaya Ueno, Hironori Kato, Megumi Takeuchi, Shin-Ichi Miyatake, Yasuhiko Tabata, Yoshio Yamaoka
Publikováno v:
Tissue Engineering; 10/01/2003, Vol. 9 Issue 5, p881-892, 12p